Pathogenesis of pulmonary vasculitis.
Peter Heeringa, Adrian Schreiber, Ronald J Falk...
https://pubmed.ncbi.nlm.nih.gov/16088492Actively Recruiting
All Genders
ID00315380
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis to Discover Biomarkers of Disease Activity
Led by University of Pennsylvania · Updated on 2026-01-23
700
Participants Needed
13
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Pennsylvania
Lead Sponsor
G
GlaxoSmithKline
Collaborating Sponsor
AI-Summary
What this Trial Is About
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune disorder causing asthma, high levels of eosinophils in the blood, and inflammation of blood vessels, affecting organs like skin, lungs, nerves, and kidneys. This research aims to find new biological markers, or biomarkers, to better assess how active the disease is in people with EGPA, improving disease monitoring and future treatment development. The study involves regular visits every 6 or 12 months where participants provide blood and urine samples. Each visit includes a physical exam, medical and medication history review, and completion of questionnaires about disease activity, health status, and lifestyle habits. These procedures help researchers identify biomarkers that reflect disease severity and response to treatment. Participants will be monitored over time with repeated assessments to track disease progression and biomarker levels. Researchers will analyze these data to discover markers that can predict clinical outcomes and guide care. The study aims to improve understanding of EGPA activity and support better management for patients during times when symptoms may not be obvious.
CONDITIONS
Brief Title
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis
- Parent or guardian willing to provide informed consent, if applicable
You will not qualify if you...
- Inability to give informed consent and to sign the consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Up to 8 years
Participants undergo regular monitoring to assess disease activity through physical exams, medical history, and questionnaires. Blood and urine samples are collected to discover biomarkers associated with eosinophilic granulomatosis with polyangiitis.
Visits every 6 months or annually
Trial Site Locations
Total: 13 locations
1
University of California San Diego
San Diego, California, United States, 92122
Completed
2
National Jewish Health
Denver, Colorado, United States, 80206
Completed
3
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Completed
4
Mayo Clinic
Rochester, Minnesota, United States, 55905
Completed
5
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Completed
6
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Completed
7
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15260
Completed
8
University of Utah
Salt Lake City, Utah, United States, 84112
Completed
9
St. Joseph's Healthcare
Hamilton, Ontario, Canada
Actively Recruiting
10
Mount Sinai Hospital
Toronto, Ontario, Canada
Completed
11
medius KLINIK KIRCHHEIM
Kirchheim unter Teck, Germany, 73230
Actively Recruiting
12
AOU Meyer IRCCS
Florence, Italy
Actively Recruiting
13
Imperial College Healthcare NHS Trust/ Imperial College London
London, United Kingdom, W12 0NN
Actively Recruiting
Loading map...
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Antineutrophil cytoplasmic antibodies (ANCA).
A Radice, R A Sinico
https://pubmed.ncbi.nlm.nih.gov/15804710Primary and secondary vasculitic neuropathy.
Gérard Said, Catherine Lacroix
https://pubmed.ncbi.nlm.nih.gov/15806339Vitamin D status in ANCA-associated vasculitis.
Irena Doubelt, David Cuthbertson, Simon Carette...
https://pubmed.ncbi.nlm.nih.gov/36874269Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis.
Irena Doubelt, Jason M Springer, Tanaz A Kermani...
https://pubmed.ncbi.nlm.nih.gov/35612893